June 4, 2019 Clinical Research/Diagn. Product Launch

New Report Sheds Light on Health Care's 'Hidden' Epidemic – Hospital Drug Diversion – and its Role in the Opioid Crisis

FRANKLIN LAKES, N.J., June 4, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in U.S. hospitals, an underreported contributor to the opioid epidemic. Hospital drug diversion, when a health care worker “diverts” opiates... Read more

June 4, 2019 PR/Corporate

BD Announces Early Tender Results

FRANKLIN LAKES, N.J., June 3, 2019 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX) (the “Company” or “BD“) today announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority set forth in the table below, up to the applicable Tender SubCap, if any, of each... Read more

April 30, 2019 Acad, Gov/Utilities Bio/Pharma/CRO PR/Corporate

BD Receives FDA Approval for Fully Sterile Chlorhexidine Gluconate Antiseptic Skin Preparation

FRANKLIN LAKES, N.J., April 30, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for BD ChloraPrep™ skin preparation with sterile solution, the only fully sterile chlorhexidine gluconate (CHG) antiseptic skin preparation commercially available in the... Read more

April 8, 2019 Bio/Pharma/CRO Product Launch

BD Unveils Platelet Quality Control Media to Help Reduce the Incidence of Sepsis in Patients Requiring Platelet Transfusion

FRANKLIN LAKES, N.J., April 8, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global availability of BD BACTEC™ platelet quality control media, which allows microbiology laboratories, blood banks and transfusion services to identify contaminated platelet units.   An estimated 12 million apheresis platelet donations are... Read more

March 26, 2019 Cell Analysis Tools Product Launch

BD Launches New Automated Flow Cytometry Sample Preparation Instrument with CE-IVD Certification

FRANKLIN LAKES, N.J., March 26, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE-IVD certification for the BD FACSDuet™ automated flow cytometry system. The new fully automated sample preparation instrument enables clinical laboratories to improve their efficiency by reducing errors and limiting the manual user interactions... Read more

March 21, 2019 Microscopy

BD Statement on Paclitaxel-Coated Devices

FRANKLIN LAKES, N.J., March 21, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to the recent letter from FDA to health care providers regarding paclitaxel-coated devices: On March 15, the FDA issued a letter to health care providers regarding paclitaxel-coated devices used... Read more

March 14, 2019 Acad, Gov/Utilities Bio/Pharma/CRO PR/Corporate

BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease

FRANKLIN LAKES, N.J., March 14, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo™ venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to... Read more